CHOLOGRAFIN MEGLUMINE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Apr 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHOLOGRAFIN MEGLUMINE is an injectable diagnostic contrast agent approved in 1954 by Bracco for radiographic imaging procedures. The product is a meglumine iodipamide formulation used to visualize biliary and hepatic structures during cholecystography and cholangiography. It functions as an iodinated contrast medium that is excreted hepatobilially, allowing real-time imaging of the biliary system.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30%), indicating a shrinking brand team and transition focus toward lifecycle management rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CHOLOGRAFIN MEGLUMINE offers limited career growth given zero linked job postings and approaching LOE status, making it a consolidation or wind-down assignment rather than a career-advancing opportunity. This role is better suited for experienced professionals managing legacy portfolios or those entering the pharmaceutical industry seeking foundational commercial experience in a stable, low-complexity product.
Brand Manager
Worked on CHOLOGRAFIN MEGLUMINE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.